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hotmail.comAbstractTo assess the effect of vitamin D supplementation on parameters of insulin sensitivity/
resistance (IS/IR) and insulin secretion in subjects with polycystic ovarian syndrome (PCOS).
A prospective double-blind randomized control trial was conducted to assess the effect of
vitamin D on insulin kinetics in women with PCOS. The trial was conducted in a tertiary care
research hospital. A total of 36 subjects with PCOS, aged 18–35 years, were included in this
study. Vitamin D3 4000 IU/day versus placebo was given once a month for 6 months and both
groups received metformin. IS (by whole-body IS index or Matsuda index), IR (by homeostasis
model assessment IR (HOMA-IR)), and insulin secretion (by insulinogenic index; II30) were
the main outcome measures. Secondary outcome included blood pressure (BP), lipid profile,
disposition index (DI), and vascular stiffness. Out of 36 subjects who consented, 32 completed
the study. Subjects were randomized into two groups: group A (nZ15; metformin and
vitamin D 4000 IU/day) or group B (nZ17; metformin and placebo). Oral glucose tolerance
tests with 75 g glucose were carried out at baseline and 6 months after supplementation.
Hypovitaminosis D was observed in 93.8% of all subjects with mean serum 25 hydroxy
vitamin D level of 7.30G4.45 ng/ml. After 6 months of vitamin D supplementation, there was
no significant difference in any of the parameters of IS/IR (area under curve (AUC)–glucose,
AUC–insulin, insulin:glucose ratio, HOMA-IR, Matsuda index, insulinogenic index, and DI),
II30, and cardiovascular risk factors between the two groups. Supplementation of vitamin D,
at a dose of 4000 IU/day for 6 months, did not have any significant effect on parameters of
IS/IR and insulin secretion in subjects with PCOS.Key Words
" PCOS
" insulin resistance
" insulin secretion
" vitamin D supplementationicen
onEndocrine Connections
(2015) 4, 108–116IntroductionVitamin D deficiency (VDD) was once thought to exclusively
affect bonemetabolism.Currently, however, there is ample evi-
dence of its role in many extra-skeletal conditions includingmetabolic syndrome, autoimmune diseases, and cancer (1).
Vitamin D receptors are recognized to be present in numerous
extra-skeletal tissues, including pancreas and muscle (2).sed under a Creative Commons
Commercial 4.0 International License.
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2–9 4 :109Vitamin D has been reported to influence not only
insulin sensitivity/resistance (IS/IR) but also insulin
secretion (3, 4, 5). There are several cross-sectional studies,
including data from the Framingham Heart Study (6),
which have demonstrated an inverse association between
serum 25 hydroxy vitamin D (S.25(OH)D) levels and IR (5).
The randomized trials conducted to study the effect of
vitamin D supplementation on IR demonstrate either no
effect or improvement in IR with supplementation (5).
Gedik & Akalin (7) reported significant improvements in
insulin secretion following vitamin D supplementation.
The most of the studies assessing effects of vitamin D
supplementation on the insulin axis have assessed IS/IR
only and that by using fasting blood samples that provide
information about hepatic IS/IR with little or no infor-
mation about peripheral insulin action. Vitamin D
supplementation is more likely to influence peripheral
IS, as demonstrated by Nagpal et al. (8), whereby three
doses of 120 000 IU vitamin D every two weeks in
comparison with placebo showed significant improve-
ments in a 3 h oral glucose tolerance test (OGTT)-derived
IS index, but not indices derived from fasting values,
in Asian–Indian men. However, these studies have been
limited by issues in design, including lack of randomiz-
ation, absence of placebo control, use of indirect measures
of insulin secretion and IS, small sample size, and inability
to show relevant increases in serum vitamin D levels.
The absence of consensus regarding optimal dosing of
vitamin D and lack of definition for optimal therapeutic
concentrations of S.25(OH)D level further inhibit the
application of vitamin D intervention trials.
Polycystic ovarian syndrome (PCOS) is now recog-
nized as one of the most common endocrinopathies in
women of reproductive agewith a prevalence of 4–10% (9).
Women with PCOS are known to be at an increased risk
for IR and present most frequently with complaints of
infertility, menstrual irregularity, hirsutism, and/or other
outward signs of androgen excess such as acne or alopecia
(10). Prevalence rates of IR have been reported to range
from 44% to 70%, though there have beenmethodological
concerns about the assessment of IR in these reports (9).
Results of cross-sectional studies in subjects with
PCOS have also indicated an inverse association between
serum vitamin D level and IR (11, 12, 13, 14). There are few
attempts to assess the effects of vitamin D supple-
mentation on IR in subjects with PCOS; however, results
are variable (15, 16, 17, 18, 19). In a recently published
randomized controlled trial of high-dose vitamin D
supplementation in PCOS, parameters of IS (QUICKI)
and IR (HOMA-IR) (20) were assessed. In women withhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0001
 2015 The author
Published by Bioscientifica LtdPCOS, especially with lean and normal BMI, hyperinsuli-
nemia is often evident only in the postprandial but not in
the fasted state, indicating that abnormalities of glucose
metabolism are likely to be missed if only fasting values
are considered (10, 21). We planned to assess effects of
vitamin D supplementation on both IR (both hepatic as
well as peripheral) and insulin secretion and cardiovas-
cular risk factors in subjects with PCOS.Material and methods
Study design
This study was conducted as a prospective randomized
double-blind placebo controlled study after obtaining
approval from the ethics committee of the institute and
written informed consent was obtained from all subjects.
The study subjects were selected from women attending
the endocrinology and gynecology outdoor services.Inclusion criteria
Subjects in the age group of 18–35 years diagnosed as
having PCOS were included in this study.
Definition of PCOS " PCOS was diagnosed as proposed
by the European Society for Human Reproduction and
Embryology and the American society for Reproductive
Medicine (Rotterdam criteria, 2003), which includes pre-
sence of two out of the following three criteria: oligo- or
chronic anovulation; clinical and/or biochemical signs
of hyperandrogenism; and polycystic ovarian appearance
on ultrasonography; with exclusion of other etiologies of
androgen excess and anovulatory infertility (22).Exclusion criteria
Subjects who were currently receiving or had received
vitamin D supplementation or treatment for PCOS
(metformin, spironolactone, oral contraceptives, or any
other drugs) in the last 6 months were excluded from the
study. Similarly, subjects with any known systemic disease
(cardiac, hepatic, endocrine including diabetes or
impaired glucose tolerance (IGT), gastrointestinal, and
renal including stones) or either currently undergoing
treatment with or having received treatment for at least
1 month in the past 6 months with medication known
to interact with vitamin D metabolism (steroids, thiazide
diuretics, phenytoin, phenobarbital, and antitubercular
drugs) were excluded from the study. Subjects who wereThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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excluded. All married females underwent a urine preg-
nancy test at the time of screening to rule out pregnancy.
Methods " Detailed history was obtained, and clinical
and anthropometric examination was carried out. Blood
samples were collected in the fasting state (minimum 8 h
fasting), followed by an oral glucose tolerance test with
sample collection at 0, 30, 60, 90, and 120 min after 75 g of
glucose ingestion. All biochemical investigations were
carried out at baseline and repeated after 6 months of
supplementation. Corrected serum total calcium and
urinary calcium:creatinine ratio were measured at baseline
and then every 8 weeks till completion. As this study
was designed as a pilot study, the sample size was fixed
as 18 subjects in each group.Intervention
Subjects were randomized (using computer generated
simple random code) into two groups: group A (met-
formin and vitamin D) or group B (metformin and
placebo) (Fig. 1). The dose of vitamin D supplementation
(only cholecalciferol was used) in group A was calculated
as 4000 IU/day but given once a month as a oral dose
(120 000 IU, Cifrol; Brown Pharmaceuticals, Delhi, India,
the monthly dose was chosen to maximize compliance),
while inert granules of equal amount and similar
appearance was used as an oral placebo. The duration ofStudy subjects
(n=40)
Randomization
(n=36)
Group A
(n=17)
Could not complete
(n=2)
Data analyzed
(n=15)
Could not complete
(n=2)
Data analyzed
(n=17)
Metformin (1500 mg/day)+vitamin D 4000
IU/day (monthly dose of 120000 IU)
Metformin (1500 mg/day)+placebo
Follow up at days 60, and 120 and a final visit at 180 days
Group B
(n=19)
Four refused to participate
Life style modification
Figure 1
Flow diagram of the study, showing numbers of study subjects who were
randomly assigned, received the intended vitamin D supplementation, and
completed the study.
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Published by Bioscientifica Ltdintervention was 6 months. Out of the total six doses,
three doses were supervised in the hospital during
monitoring visits, while three doses were taken on fixed
days at home, which were confirmed by telephonic
contact. Both groups received similar life style modifi-
cation advice including consultation with a qualified
dietician before randomization.
In both arms, metformin was initiated at a dose of
500 mg twice a day for the first 2 weeks followed by
500 mg three times a day, which was continued for
6 months without any change. Adherence to medication
was assured by maintaining a diary to record daily timings
of ingestion of metformin.
Safety of proposed intervention " The two main
safety issues of proposed intervention, hypercalcemia,
and hypercalciuria were assessed by measurement of
corrected serum total calcium and urinary calcium:creati-
nine ratio (non-fasting, second void sample) at baseline
and then every 8 weeks and at the completion of
intervention. Hypercalcemia was defined as serum
calcium levels more than 10.4 mg/dl and hypercalciuria
as urinary calcium:creatinine ratio more than 0.4 (mg/mg;
(23)), which was considered as abnormal. Subjects with
a urinary calcium:creatinine ratio of over 0.4 without
hypercalcemia were re-evaluated with a timed 24 h urine
calcium excretion (over 4 mg/kg excretion was considered
as abnormal). If 24 h calcium excretion was within the
normal limits, the subject continued in the study. Any
subject, who developed both hypercalcemia and hyper-
calciuria, was excluded from further intervention and
referred to the physician for standard management.
Anthropometric measurements " All measurements
were made with subjects dressed in minimal light clothing
but without footwear. Height was measured with Holtain’s
stadiometer (Holtain, Inc., Crymych, Pembrokeshire, UK).
Weight was measured with the same digital weighing
machine. BP was measured in the right upper limb in the
sitting position using a mercury sphygmomanometer after
5-min rest with an appropriate size cuff. BP was measured
three times and the mean value of second and third
recordings was considered.Parameters of IR
i) IR – was calculated by a computer-basedmodel called
HOMA-IR utilizing fasting blood glucose and fasting
serum insulin levels (24).This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research G Garg et al. Vitamin D supplementation
in PCOS
4–9 4 :111ii) The whole-body IS index (WBISI) or Matsuda index –
this composite WBISI was calculated by the formula
suggested by Matsuda & DeFronzo (25).
iii) AUC – was calculated for blood glucose (0, 30, 60, 90,
and 120 min) and serum insulin (0, 30, 60, 90, and
120 min) using the trapezoidal rule. Fasting srum
insulin and blood glucose levels were used to
calculate the insulin glucose ratio.
iv) Insulin secretion – was assessed by ‘insulinogenic
index’ (II30), which is the change in insulin levels
divided by the change in glucose over the first 30 min
of the OGTT (26) and was expressed as II30 (mIU/l per
mg per dl)ZD insulin 0–30/D glucose 0–30).
v) Disposition index (DI) – reflects the ability of the
b-cell to compensate for IR and represent b-cell
function (27). It is calculated by mathematical
formula of insulin secretion!IS (both these para-
meters were calculated separately).Assessment of vascular stiffness
Vascular stiffness was assessed by pulse wave transit time
analysis to determine aortic augmentation index (AIx) and
pulse wave velocity (PWV) as suggested by international
guidelines (28). All measurements were made on the right
side and by a single observer using the SphygmoCors
Cardiovascular Management System (AtCor Medical,
Sydney, Australia). The AIx was calculated as augmented
pressure (tonometrically derived) divided by central pulse
pressure multiplied by 100 to give a percentage value
for comparison. As AIx is a ratio of three aortic pressure
values, the influence of any systematic errors in the
estimation of aortic pulse pressure by the transfer function
will beminimal (29). As AIx is influenced by heart rate, the
corrected index for heart rate, 75 beats/min (AI at 75), was
used. Carotid-femoral PWV was calculated by dividing
distance (m) by transit time (s) and expressed as m/s.
PWV is inversely related to vascular compliance. Hence,
a stiffer vessel will conduct the pulse wave faster than a
more distensible and compliant vessel.
Biochemical analysis " Complete blood counts, liver
and renal function tests, serum calcium (corrected calcium
with serum albumin), phosphate, total alkaline phospha-
tase, and blood glucose weremeasured in all subjects using
an automated chemistry analyzer (Roche Hitachi 912
Chemistry Analyzer, GMI, Inc., Ramsey, MN, USA). Serum
insulin was measured on an auto analyzer (Roche Elecsys
2010) by electrochemiluminometric assay (CV for thishttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0001
 2015 The author
Published by Bioscientifica Ltdmethod 2.1–2.8%). Serum total cholesterol, triglyceride,
and HDL cholesterol (HDL-C) levels were estimated
directly using an automated analyzer, while LDL choles-
terol (LDL-C) was estimated using the Friedewald equation
(30). Urinary calcium was measured by the colorimetric
method and urinary creatinine by the liquid kinetic
method. Serum intact parathyroid hormone (PTH) was
measured using an electrochemiluminometric labeled
tracer on a Roche-Cobas 411e auto-analyzer. S.25(OH)D
was measured on the DiaSorin auto analyzer (‘LIASON’
DiaSorin, Inc., Stillwater, MN, USA) using a chemi-
luminescent label. The reproducibility of the assay ranged
from 6% to 12% and was within the performance
characteristics described by the manufacturer. Our labora-
tory is registered with the UK-DEQAS vitamin D assay
external quality control assessment program and hence
met their performance targets regularly (www.deqas.org).
VDD was defined as a S.25(OH)D level !20 ng/ml.
This was further subdivided into severe, moderate, and
mild VDD if S.25(OH)D levels were !5, 5–!10, and
10–!20 ng/ml respectively, while levels between 20
and 30 ng/ml were considered as insufficiency and O30
as vitamin D sufficient (31).Statistical analysis
Baseline data are expressed as meanGS.D., or median and
range, as appropriate. Continuous variables not showing
normal distribution were log transformed for analysis.
Comparisonofmeanswas performedusing Student’s t-test.
Categorical variables were compared using the c2 test or
Fisher’s exact test as appropriate. For variables such as
urinary calcium:creatinine ratio, serumDHEAS, HOMA-IR,
and Matsuda index, log-transformed variables were used
for analysis using Student’s t-test for comparison between
groups. For fasting plasma insulin, the Wilcoxon’s rank-
sum test was used for comparison between the groups.
The outcome parameters were compared between the
two groups as to their levels at 6 months after supple-
mentation using Student’s t-test/Wilcoxon’s rank-sum
test. For testing all hypotheses, tests were two-tailed and
a P value of 0.05 was considered statistically significant.
Analysis was performed using Stata 12.0 (College Station,
TX, USA).Results
Consecutive subjects attending the Gynecology and
Endocrinology Outpatient Department were screened for
PCOS. Forty subjects satisfying the inclusion criteria wereThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Table 1 Baseline demographic characteristics of study
subjects.
Characteristics GroupA (nZ15) Group B (nZ17) P value
Age (years) 22.0G4.61 22.8G4.56 0.64
BMI (kg/m2) 26.8G4.56 26.7G6.11 0.96
History of menstrual
irregularity (n)
15 14 0.23
Hirsutism (n) 5 10 0.18
Acne (n) 7 11 0.48
History of weight
gain (n)
13 12 0.40
Polycystic appearance
on USG (n)
13 16 0.58
USG, ultrasonography.
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5–9 4 :112requested to participate in the study, of which 36 subjects
provided consent for participation. Seventeen subjects
were randomized to group A (metforminCvitamin D) and
19 to group B (metforminCplacebo) (Fig. 1). Two subjects
in each group were lost to follow up, leaving 32 subjects
to complete the study (group A, nZ15; group B, nZ17).
One subject in each of the two groups wasmore concerned
about their irregular menstrual cycles and opted for treat-
ment (started oral contraceptive pills) for regularization
of cycles. One subject in group A started anti-androgen
therapy for acne while one subject in group B moved out
of the city and dropped out. All doses of intervention as
well as placebo were taken on fixed days. Baseline
demographic parameters of study subjects are shown in
Table 1. Comparisons of biochemical parameters at
baseline and 6 months after supplementation in both
the groups are shown in Table 2.Vitamin D deficiency
VDD (!20 ng/ml) was observed in 93.8% of all subjects,
while vitamin D insufficiency was observed in the
remaining 6.2% of subjects. Among 32 subjects who
completed the study, 13 (40.3%) had severe VDD while
16 (50%) had moderate VDD. No significant difference
in S.25(OH)D level or proportion of VDD was observed
between the two groups at baseline.
Secondary hyperparathyroidism (S.iPTH O55 pg/ml)
was observed in 53.3% of subjects in group A and in 41.1%
of subjects in group B (PZ0.54).Impaired glucose tolerance
At baseline, three subjects in group A and one subject in
group B had IGT but none of the study subjects had
impaired fasting glucose. All three subjects in group A hadhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0001
 2015 The author
Published by Bioscientifica Ltdnormal glucose tolerance at 6 months of follow-up, while
one subject in group B who had IGT at baseline continued
having IGT at 6 months.Correlation between serum vitamin D and parameters of
IS/IR and insulin secretion at baseline
Parameters of IS/IR (AUC–glucose, AUC–insulin, insulin
glucose ratio, HOMA-IR, Matsuda index, and DI) and
insulin secretion (II30) did not show any significant
correlation (Spearman’s rank test) with serum vitamin D
level at baseline. Similarly, serum PTH also did not have
any significant correlation with these parameters.Safety of intervention
Three subjects in group A and one in group B had spot
urine calcium:creatinine ratios exceeding 0.4 at 6 months,
but all of these subjects had 24 h urinary calcium excretion
in the normal range. None of the subjects developed
hypercalcemia at any time point of the study. Metformin
was well tolerated and no side effects were reported.Follow-up after 24 weeks of intervention
There was no significant difference in any of the
parameters of IS/IR and insulin secretion between the
two groups at the end of 6 months. Similarly, there was no
statistically significant difference between the two groups
in BP, lipid profile, and parameters of vascular stiffness.
In group A, S.25(OH)D significantly increased
(P%0.001) and serum PTH decreased (P%0.001) at
6months in comparison to group B. As secondary analysis,
a statistically significant decrease in serum insulin level
and HOMA-IR was observed at 6 months in comparison
to baseline values in group A but not in group B.
Secondary hyperparathyroidism was present in 26.2%
of subjects in group A and 29.4% in group B (PZ0.78).
The difference in change between the two groups (mean
and CI) is shown in Table 2.
Similarly, there was no significant difference in serum
total testosterone between the two groups at the end of
6 months. However, a significant decrease in serum total
testosterone (PZ0.03)was observed in groupA at 6months in
comparison to baseline but was not observed in group B.Discussion
In this study, we assessed the effects of vitamin D
supplementation on parameters of IS/IR and insulinThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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7–9 4 :114secretion in subjects with PCOS. The results of our study
indicate that vitamin D supplementation given at doses
of 4000 IU/day (given once a month) for 6 months
to vitamin D deficient/insufficient subjects with PCOS
did not have any significant effects on parameters of
IS/IR and insulin secretion despite normalization of
s.25(OH)D levels.
A high prevalence of VDD has been reported all over
India for all age groups including neonates, infants,
school-going children, adolescents, adults, pregnant and
lactating women, and senior citizens. This is probably
a result of poor sun exposure, dark skin complexion,
atmospheric pollution, vegetarian food habits, absence
of food fortification with vitamin D, and poor intake of
vitamin D supplements (32). Consistent with these
observations, VDD was observed in 93.8% of all subjects
while the rest had vitamin D insufficiency. In our study,
subjects in group A received supplementation with
4000 IU of vitamin D/day, resulting in a significant
increase in mean S.25(OH)D levels from 7.73 to
31.54 ng/ml at 6 months with a significant fall in PTH
(mean change of 16.62 pg/ml) from baseline. However,
mean S.25(OH)D levels and PTH levels did not change
significantly in group B.
The effects of vitamin D supplementation on IR
and IS in subjects with PCOS have been investigated in a
small number of studies (15, 16, 17, 18, 19). All studies
except one have failed to find a significant effect of vitamin
D supplementation on IS parameters. However, it would be
difficult to compare results with these studies as the dose
and duration of vitamin D supplementation were quite
variable among the studies and, only in three studies (15,
16, 20), subjects were randomized. In a recently published
randomized placebo controlled trial, Raja-Khan et al. (20),
using a high dose of vitamin D (12 000 IU/day) for
12 weeks, also did not find any significant difference in IS.
In the only study where vitamin D supplementation
resulted in a decrease in IR, the results were of borderline
significance (PZ0.043). In this study, Selimoglu et al. (18)
administered a single oral dose of 300 000 IU of vitamin
D3 to 11 womenwith PCOS (mean age 23.6G5.7 years and
BMI 33.9G5.1 kg/m2). Three weeks after administration of
vitamin D, while IR (as measured by HOMA-IR) decreased
significantly (PZ0.043), there was no significant
difference in fasting insulin and glucose levels.
A significant decrease in fasting serum insulin levels in
group A was observed after vitamin D supplementation
(PZ0.009), which resulted in borderline decrease in
HOMA-IR (0.03). A similar decrease in insulin levels after
vitamin D supplementation has also been reported byhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0001
 2015 The author
Published by Bioscientifica LtdRaja-Khan et al. (20). Although it would be difficult to
identify from studies of small sample size, a direct effect of
vitamin D on insulin secretion is possible. Both of these
studies are similar in design, but there were some
important noticeable differences. The mean S.25(OH)D
level was much lower in our study with the presence of
VDD in 93% study subjects. Similarly, BMI was also hugely
different in both these studies with a much lower BMI
in our study (mean BMI was 37.20G4.53 and 35.09G
9.81 kg/m2 versus 26.8G4.56 and 26.7G4.56 kg/m2 in the
vitamin D and placebo groups respectively).
The reports of the few studies that havemeasured AUC
for glucose and insulin (17, 19), in addition to calculating
IR parameters from fasting serum insulin and blood
glucose, did not describe any significant effect. In our
study, both AUC–glucose and AUC–insulin were not
different between the two groups after intervention.
Although results from our study indicate an improve-
ment in DI after vitamin D supplementation in group A,
it was not statistically significant. Our study being a pilot
project was not powered enough to detect a significant
difference in the parameters of insulin kinetics.
PCOS has been reported to be associated with factors
of increased cardiovascular risk, such as IR, dyslipidemia,
and type 2 diabetes (33, 34, 35). PCOS has also been
suggested to be associated with increased arterial stiffness,
although whether this association is independent of
obesity or not is not certain (36). In our study, we did
not find any significant difference between lipid profile
and parameters of vascular stiffness between the two
groups after vitamin D supplementation. Similar results
of changes in lipid parameters were also reported by
Raja-Khan et al. (20).
Thus, in our study, like previous studies in subjects
with PCOS, there was no significant effect of vitamin D
supplementation on parameters of IS/IR and insulin
secretion.
Although there was no significant difference in
serum testosterone between the two groups at baseline
or at 6 months, a significant fall in serum testosterone
was observed in group A at 6 months in comparison
with the baseline in the same group. A similar result has
also been described in a study by Pal et al. (17). However,
others (19, 37) have observed no effect on serum
testosterone levels. A direct effect of vitamin D on the
steroidogenesis pathway (ovarian and/or adrenal) has
been proposed to explain the observed reduction in
circulating androgens (17).
None of the study subjects developed clinical or
biochemical evidence of hypercalcemia at any timeThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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8–9 4 :115during supplementation While three subjects in group A
and one in group B had spot urine calcium:creatinine
ratios exceeding 0.4, none of them had elevated 24 h
urinary calcium excretion or hypercalcemia. This indicates
that the doses used in our study are safe and effective
for improving S.25(OH)D levels. Wehr et al. (19), using
vitamin D dose of 20 000 IU once a week for 24 weeks,
reported that, in one subject at 12 weeks and in another
subject at 24 weeks, S.25(OH)D levels were found to be
in excess of 100 ng/ml. However, both these subjects
remained normocalcemic throughout the study. The
mean S.25(OH)D levels of study subjects were 28G
11 ng/ml, which were higher than the mean S.25(OH)D
levels of our subjects.
To the best of our knowledge, this is the first study
evaluating effects of vitamin D supplementation on both
IS/IR and insulin secretion parameters derived from both
fasting and post-glucose challenge and cardiovascular risk
factors in subjects with PCOS. The double-blind placebo
controlled design, use of both fasting- and OGTT-derived
parameters, and 6 months of supplementation duration
are the main strengths of our study, but being a pilot study
in design, it was not powered to detect a significant
difference in outcome measures. Hence, small sample size
and lack of power were major limitations. Another
limitation was the use of metformin in both study
groups along with vitamin D/placebo, which might
have overruled a small positive effect of vitamin D on IS.
As all subjects were symptomatic (oligomenorrhea and
hirsutism), it was decided to treat them along with
administering vitamin D/placebo.
Although our results indicate no significant difference
in outcomes between the two groups they need to be
interpreted cautiously in view of the small sample size
and the study power for comparison of outcomes being
meager, the maximum being only 27% for comparison
of HOMA-IR. Another important limitation was very few
subjects with IGT (three in group A and one in group B).
In conclusion, we did not find any beneficial effects of
vitamin D supplementation on parameters of IS in women
with PCOS. However, studies with larger sample sizes and
adequate power may detect possible therapeutic benefits
of vitamin D supplementation on IR and b-cell function in
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